vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Velo3D, Inc. (VELO). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $9.4M, roughly 1.6× Velo3D, Inc.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -231.9%, a 233.7% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -25.2%). CHAMPIONS ONCOLOGY, INC. produced more free cash flow last quarter ($-2.0M vs $-8.3M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -1.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Velo3D, Inc. develops and sells advanced end-to-end metal additive manufacturing (3D printing) solutions, comprising industrial-grade printers, specialized processing software, and high-performance metal materials. It primarily serves global aerospace, defense, energy, semiconductor and industrial manufacturing markets, enabling customers to produce complex, high-precision metal parts that are difficult to manufacture with traditional methods.
CSBR vs VELO — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $9.4M |
| Net Profit | $268.0K | $-21.9M |
| Gross Margin | 51.7% | -73.6% |
| Operating Margin | 1.2% | -231.0% |
| Net Margin | 1.8% | -231.9% |
| Revenue YoY | 11.5% | -25.2% |
| Net Profit YoY | -63.2% | -2.9% |
| EPS (diluted) | $0.02 | $-0.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $9.4M | ||
| Q3 25 | $14.0M | $13.6M | ||
| Q2 25 | $12.4M | $13.6M | ||
| Q1 25 | $17.0M | $9.3M | ||
| Q4 24 | $13.5M | $12.6M | ||
| Q3 24 | $14.1M | $8.2M | ||
| Q2 24 | $14.0M | $10.3M | ||
| Q1 24 | $12.0M | $9.8M |
| Q4 25 | $268.0K | $-21.9M | ||
| Q3 25 | $-436.0K | $-11.2M | ||
| Q2 25 | $-1.8M | $-13.3M | ||
| Q1 25 | $4.5M | $-25.0M | ||
| Q4 24 | $728.0K | $-21.3M | ||
| Q3 24 | $1.3M | $-21.9M | ||
| Q2 24 | $-109.0K | $935.0K | ||
| Q1 24 | $-2.5M | $-27.5M |
| Q4 25 | 51.7% | -73.6% | ||
| Q3 25 | 42.9% | 3.2% | ||
| Q2 25 | 41.1% | -11.7% | ||
| Q1 25 | 61.2% | 7.5% | ||
| Q4 24 | 44.9% | -3.5% | ||
| Q3 24 | 49.7% | 49.4% | ||
| Q2 24 | 48.2% | -28.0% | ||
| Q1 24 | 34.7% | -28.8% |
| Q4 25 | 1.2% | -231.0% | ||
| Q3 25 | -3.8% | -73.3% | ||
| Q2 25 | -16.2% | -85.4% | ||
| Q1 25 | 26.4% | -123.6% | ||
| Q4 24 | 5.4% | -167.0% | ||
| Q3 24 | 9.5% | -213.8% | ||
| Q2 24 | -1.9% | -187.7% | ||
| Q1 24 | -21.4% | -211.1% |
| Q4 25 | 1.8% | -231.9% | ||
| Q3 25 | -3.1% | -82.0% | ||
| Q2 25 | -14.9% | -97.7% | ||
| Q1 25 | 26.4% | -268.4% | ||
| Q4 24 | 5.4% | -168.5% | ||
| Q3 24 | 9.3% | -265.3% | ||
| Q2 24 | -0.8% | 9.0% | ||
| Q1 24 | -21.1% | -281.2% |
| Q4 25 | $0.02 | $-0.87 | ||
| Q3 25 | $-0.03 | $-0.65 | ||
| Q2 25 | $-0.12 | $-0.94 | ||
| Q1 25 | $0.31 | $-1.87 | ||
| Q4 24 | $0.05 | $7.06 | ||
| Q3 24 | $0.09 | $-35.52 | ||
| Q2 24 | $-0.01 | $1.65 | ||
| Q1 24 | $-0.19 | $-55.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $39.0M |
| Total DebtLower is stronger | — | $31.0M |
| Stockholders' EquityBook value | $4.2M | $38.2M |
| Total Assets | $30.2M | $105.3M |
| Debt / EquityLower = less leverage | — | 0.81× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $39.0M | ||
| Q3 25 | $10.3M | $11.8M | ||
| Q2 25 | $9.8M | $854.0K | ||
| Q1 25 | $3.2M | $3.9M | ||
| Q4 24 | $2.8M | $1.2M | ||
| Q3 24 | $2.9M | $1.6M | ||
| Q2 24 | $2.6M | $3.2M | ||
| Q1 24 | $4.5M | $10.9M |
| Q4 25 | — | $31.0M | ||
| Q3 25 | — | $23.0M | ||
| Q2 25 | — | $22.5M | ||
| Q1 25 | — | $21.7M | ||
| Q4 24 | — | $5.7M | ||
| Q3 24 | — | $32.3M | ||
| Q2 24 | — | $33.5M | ||
| Q1 24 | — | $44.0M |
| Q4 25 | $4.2M | $38.2M | ||
| Q3 25 | $3.5M | $29.9M | ||
| Q2 25 | $3.8M | $21.4M | ||
| Q1 25 | $5.5M | $32.8M | ||
| Q4 24 | $681.0K | $39.7M | ||
| Q3 24 | $-332.0K | $34.4M | ||
| Q2 24 | $-1.9M | $52.1M | ||
| Q1 24 | $-2.1M | $45.5M |
| Q4 25 | $30.2M | $105.3M | ||
| Q3 25 | $30.5M | $93.7M | ||
| Q2 25 | $32.3M | $78.4M | ||
| Q1 25 | $30.6M | $91.3M | ||
| Q4 24 | $25.2M | $89.2M | ||
| Q3 24 | $24.9M | $110.8M | ||
| Q2 24 | $26.1M | $116.7M | ||
| Q1 24 | $26.8M | $136.1M |
| Q4 25 | — | 0.81× | ||
| Q3 25 | — | 0.77× | ||
| Q2 25 | — | 1.05× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.94× | ||
| Q2 24 | — | 0.64× | ||
| Q1 24 | — | 0.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-7.7M |
| Free Cash FlowOCF − Capex | $-2.0M | $-8.3M |
| FCF MarginFCF / Revenue | -13.1% | -88.3% |
| Capex IntensityCapex / Revenue | 1.6% | 6.4% |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-7.7M | ||
| Q3 25 | $600.0K | $-6.0M | ||
| Q2 25 | $6.9M | $-1.2M | ||
| Q1 25 | $490.0K | $-12.3M | ||
| Q4 24 | $-283.0K | $-2.2M | ||
| Q3 24 | $311.0K | $-2.0M | ||
| Q2 24 | $-1.8M | $-8.0M | ||
| Q1 24 | $-919.0K | $-20.5M |
| Q4 25 | $-2.0M | $-8.3M | ||
| Q3 25 | $554.0K | $-6.3M | ||
| Q2 25 | $6.6M | $-3.0M | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | $-2.2M | ||
| Q3 24 | — | $-2.0M | ||
| Q2 24 | $-1.8M | $-8.0M | ||
| Q1 24 | $-1.0M | $-20.5M |
| Q4 25 | -13.1% | -88.3% | ||
| Q3 25 | 4.0% | -46.5% | ||
| Q2 25 | 53.5% | -22.2% | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | -17.7% | ||
| Q3 24 | — | -24.2% | ||
| Q2 24 | -13.0% | -77.1% | ||
| Q1 24 | -8.4% | -209.8% |
| Q4 25 | 1.6% | 6.4% | ||
| Q3 25 | 0.3% | 2.3% | ||
| Q2 25 | 2.0% | 13.3% | ||
| Q1 25 | 0.2% | 0.0% | ||
| Q4 24 | 0.7% | 0.2% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.8% | 0.1% |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | -8.52× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
VELO
Segment breakdown not available.
